Describing the unique “capital light” business model and its advantages

The use of artificial intelligence in the drug discovery process, deals signed with AI partners, and upcoming milestones for AI analysis

Progress of POLB 001, including the completion of its human challenge study without serious adverse events and aims to be partner-ready in 2023

What’s next on the road to POLB 001 commercialisation

The advantages of orally delivered vaccines, Poolbeg’s collaboration with encapsulation specialist AnaBio on obesity and diabetes treatments, and plans for an exploratory trial in 2023

Progress on other drugs in the pipeline, POLB 002 and POLB 003